Hiv And Tuberculosis Hesi Case Study

The HIV and tuberculosis HESI case study provides a valuable learning opportunity for nursing students who must integrate knowledge of immunology, infectious disease, and pharmacology while applying clinical judgment. Still, this case typically presents a young adult with a newly diagnosed HIV infection who develops symptoms suggestive of pulmonary tuberculosis, prompting an evaluation of dual therapy, infection control, and patient education. By working through the scenario, learners practice assessing laboratory data, prioritizing nursing interventions, and anticipating potential complications such as drug interactions or immune reconstitution inflammatory syndrome (IRIS). The following sections break down the essential components of the case, offering a structured approach that mirrors the thought process required for success on the HESI examination and in real‑world practice.

Overview of the Case Scenario

In the HIV and tuberculosis HESI case study, the patient is often a 28‑year‑old male who reports a two‑week history of low‑grade fever, night sweats, weight loss, and a productive cough. He mentions occasional shortness of breath on exertion and denies recent travel or known TB exposure. His past medical history reveals a positive HIV test three months ago, with a CD4 count of 180 cells/µL and a viral load of 45,000 copies/mL. Now, he is not currently on antiretroviral therapy (ART) because he was lost to follow‑up after diagnosis. In real terms, on physical examination, he appears thin, with bilateral apical crackles and mild lymphadenopathy. But a sputum smear for acid‑fast bacilli (AFB) returns positive, and a chest X‑ray shows cavitary lesions in the upper lobes. The case then guides the student through confirming the diagnosis, initiating appropriate therapy, and addressing nursing priorities.

Pathophysiology of HIV‑TB Co‑infection

Understanding the interplay between HIV and Mycobacterium tuberculosis is crucial for interpreting clinical findings and planning care.

Immunologic Impact

• HIV progressively depletes CD4⁺ T lymphocytes, weakening cell‑mediated immunity that normally contains TB infection.
• When CD4 counts fall below 200 cells/µL, the risk of developing active tuberculosis rises sharply, often presenting with atypical or extrapulmonary manifestations.

Microbiologic Dynamics

• Mycobacterium tuberculosis can remain latent in granulomas; HIV‑induced immunosuppression disrupts granuloma integrity, allowing bacterial replication.
• The bacterial load increases, enhancing transmissibility and the likelihood of cavitary lung disease, as seen in the case study.

Clinical Consequences

• Co‑infection accelerates HIV replication, leading to higher viral loads and faster disease progression.
• Conversely, active TB can trigger immune activation that further suppresses HIV‑specific responses, creating a vicious cycle.

Clinical Presentation and Diagnostic Workup

Recognizing the hallmark signs and selecting appropriate tests are key steps in the HIV and tuberculosis HESI case study.

Typical Symptoms

• Persistent cough (>2–3 weeks) possibly productive of sputum or blood
• Fever, chills, night sweats
• Unexplained weight loss (>10% of body weight)
• Fatigue and malaise

Physical Examination Findings

• Lymphadenopathy (especially cervical or supraclavicular)
• Lung auscultation: crackles, bronchial breath sounds, or wheezing
• Signs of weight loss and muscle wasting

Diagnostic Tests | Test | Purpose | Expected Result in Case |

|------|---------|--------------------------| | Sputum AFB smear & culture | Detect mycobacteria | Positive smear; culture grows M. tuberculosis after 2–4 weeks | | Chest X‑ray or CT | Identify pulmonary involvement | Upper‑lobe cavitary lesions or infiltrates | | HIV ELISA/Western blot | Confirm HIV status | Positive | | CD4 count & viral load | Assess immunosuppression | CD4 180 cells/µL; VL 45,000 copies/mL | | Interferon‑gamma release assay (IGRA) or tuberculin skin test (TST) | Screen for latent TB | Often positive, but may be false‑negative in severe immunosuppression | | Liver function tests (LFTs) & baseline vision | Monitor for drug toxicity | Obtained before starting therapy |

Nursing Priorities and Interventions

The HIV and tuberculosis HESI case study emphasizes a systematic nursing approach that addresses infection control, medication management, symptom relief, and psychosocial support.

Infection Control * Place the patient in an airborne infection isolation room (AIIR) with negative pressure. * Ensure staff and visitors wear N95 respirators; educate the patient on cough etiquette and mask use.

• Monitor adherence to isolation precautions until the patient is deemed non‑infectious (typically after two weeks of effective therapy and three consecutive negative sputum smears).

Medication Management

• Antitubercular Therapy (ATT): Initiate a standard four‑drug regimen—isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB)—for the first two months, followed by INH and RIF for four months.
• Antiretroviral Therapy (ART): Start ART within 2–8 weeks of TB treatment, depending on CD4 count and clinical stability; common regimens include a nucleoside reverse transcriptase inhibitor (NRTI) backbone plus an integrase strand transfer inhibitor (INSTI) or a non‑nucleoside reverse transcriptase inhibitor (NNRTI).
• Drug Interaction Vigilance: Rifampin induces hepatic enzymes, reducing levels of certain ART agents (e.g., protease inhibitors, some NNRTIs). Choose rifampin‑compatible ART (e.g., efavirenz or dolutegravir with dose adjustment) or consider rifabutin as a substitute.
• Administration: Observe directly observed therapy (DOT) for ATT to ensure adherence; assess for side effects such as hepatotoxicity, peripheral neuropathy, optic neuritis, and hyperuricemia.

Symptom Control and Comfort

• Administer antipyretics (acetaminophen) for fever as needed.
• Provide supplemental oxygen if SpO₂ falls below 90%.
• Encourage adequate hydration and nutrition; collaborate with dietetics for high‑calorie, high‑protein meals to counteract wasting.
• Teach cough‑assist techniques and positioning to improve clearance.

Laboratory and Diagnostic Monitoring * Obtain baseline L

Laboratory and Diagnostic Monitoring (Continued)

FTs & baseline vision were obtained prior to initiation of therapies, as outlined in the initial assessment. Ongoing monitoring is crucial to assess treatment efficacy and detect potential adverse effects. This includes:

Continue exploring with our guides on who killed yew case study page 3 phases and why milk is white in colour.

• Sputum Cultures: Obtain regular sputum cultures (at least weekly initially, then less frequently) to monitor for treatment response and drug resistance. A negative sputum smear and culture after two weeks of effective therapy is a key indicator of treatment success.
• CD4 Count & Viral Load: Repeat CD4 count and viral load monitoring every 3-6 months to assess the impact of ART on immune function and HIV replication. A rising CD4 count and decreasing viral load demonstrate effective antiretroviral therapy.
• Liver Function Tests (LFTs): Monitor LFTs periodically, especially during ATT, to assess for hepatotoxicity from rifampin, pyrazinamide, and ethambutol. Elevated LFTs may necessitate dose adjustments or discontinuation of the offending agent.
• Renal Function Tests (RFTs): Monitor creatinine and BUN levels, particularly with pyrazinamide, to assess for nephrotoxicity.
• Peripheral Neuropathy Assessment: Regularly assess for peripheral neuropathy, especially with isoniazid. This can be done through patient questioning about numbness, tingling, or pain in the extremities, and potentially with nerve conduction studies if indicated.
• Vision Assessment: Monitor for optic neuritis, particularly with ethambutol. Assess visual acuity and color perception.
• Drug Resistance Testing: If treatment failure is suspected, perform drug resistance testing to identify specific mutations that confer resistance to the current regimen. This information guides the selection of alternative treatment strategies.

Psychosocial Support

The patient's diagnosis of both HIV and TB presents significant psychosocial challenges. A holistic approach necessitates addressing emotional well-being and social support needs.

• Emotional Support: Provide a safe and non-judgmental environment for the patient to express feelings of anxiety, depression, fear, and stigma. Encourage open communication and active listening.
• Stigma Reduction: Address potential stigma associated with both HIV and TB. Provide education about these infections and advocate for patient rights and confidentiality.
• Social Support: Assess the patient's social support network and connect them with resources such as support groups, community organizations, and case management services.
• Financial Assistance: TB and HIV treatment can be expensive. Assist the patient in accessing financial assistance programs to cover medication costs, transportation, and other essential needs.
• Cultural Sensitivity: Recognize and respect the patient's cultural beliefs and practices. Adapt communication and care plans to be culturally appropriate.

Conclusion

Managing a patient co-infected with HIV and tuberculosis requires a comprehensive and coordinated approach. Successful outcomes depend on close collaboration between the healthcare team, the patient, and their support network. This case highlights the importance of meticulous assessment, proactive infection control measures, diligent medication management, attentive symptom control, and strong psychosocial support. Continued education, adherence to evidence-based guidelines, and a patient-centered focus are essential for effective care. By addressing the complex interplay of these factors, nurses play a vital role in improving the quality of life and achieving optimal health outcomes for individuals living with this challenging co-infection. When all is said and done, the goal is to achieve viral suppression, TB eradication, and improved overall well-being, empowering the patient to live a full and productive life.